Syndax Pharma (SNDX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
13.33 +0.03 (+0.23%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 13.33 unch (unch) 16:27 ET
for Fri, Apr 25th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -318,758 | -209,360 | -149,338 | 24,926 | -73,158 |
Depreciation Amortization | -13,430 | -14,791 | -3,349 | 687 | -41 |
Accounts receivable | -11,237 | N/A | N/A | N/A | N/A |
Accounts payable and accrued liabilities | 1,665 | 5,611 | -1,319 | 2,161 | -2,670 |
Other Working Capital | 12,807 | 31,860 | 1,656 | -9,597 | -7,934 |
Other Operating Activity | 54,050 | 26,079 | 18,675 | 10,954 | 12,543 |
Operating Cash Flow | $-274,903 | $-160,601 | $-133,675 | $29,131 | $-71,260 |
Cash Flows From Investing Activities | |||||
Change In Deposits | -219,775 | 117,609 | -186,413 | -40,744 | -142,530 |
PPE Investments | N/A | N/A | 225 | -129 | N/A |
Investing Cash Flow | $-219,775 | $117,609 | $-186,188 | $-40,873 | $-142,530 |
Cash Flows From Financing Activities | |||||
Debt Issued | 343,652 | N/A | N/A | 576 | 19,730 |
Debt Repayment | N/A | N/A | -20,996 | N/A | N/A |
Common Stock Issued | 9,715 | 264,132 | 193,250 | 117,888 | 284,693 |
Other Financing Activity | 0 | 0 | 0 | 0 | 1 |
Financing Cash Flow | $353,367 | $264,132 | $172,254 | $118,464 | $304,424 |
Beginning Cash Position | 295,611 | 74,471 | 222,080 | 115,358 | 24,724 |
End Cash Position | 154,300 | 295,611 | 74,471 | 222,080 | 115,358 |
Net Cash Flow | $-141,311 | $221,140 | $-147,609 | $106,722 | $90,634 |
Free Cash Flow | |||||
Operating Cash Flow | -274,903 | -160,601 | -133,675 | 29,131 | -71,260 |
Capital Expenditure | N/A | N/A | N/A | -129 | N/A |
Free Cash Flow | -274,903 | -160,601 | -133,675 | 29,002 | -71,260 |